Skip to main content
SpringerLink
Log in

An Overview of Community Pharmacist Interventions

Assessing Cost-Effectiveness and Patients’ Willingness To Pay

  • Review Article
  • Published:
Disease Management & Health Outcomes

Abstract

This article evaluates the cost effectiveness of and patients’ willingness to pay for interventions by community pharmacists in the overall context of pharmaceutical care. The rationale for interventions by pharmacists in patient care is examined from the viewpoint of clinical and economic needs of the healthcare system. The philosophy of the practice of pharmaceutical care is compared with that of disease management. The analysis shows that both clinical and economic deficiencies exist in the current healthcare system that the practice of pharmaceutical care could help to rectify. More importantly, there is congruence in the practice philosophies between pharmaceutical care and disease management, with both being patient centered and outcome focused. Therefore, the practice of pharmaceutical care can be facilitated within the context of disease management.

There are many examples showing that interventions by community pharmacists can result in cost savings. However, there are few studies on consumers’ willingness to pay for such services provided; those to date suggest that consumers are willing to pay a modest amount for pharmaceutical care provided by community pharmacists.

Barriers for implementing pharmaceutical care by community pharmacists are discussed, and some suggestions of strategies to be adopted for the successful implementation of pharmaceutical care are made. The author is of the view that before full reimbursement for pharmaceutical care is achieved, the successful implementation of pharmaceutical care by community pharmacists will hinge on better utilization of available resources and improvement in communications between pharmacists, patients and other healthcare professionals. Coordinated and systematic efforts would be required to collect information regarding consumers’ willingness to pay in order to assist in negotiating an acceptable level of reimbursement.

Finally, in this age of accountability in healthcare, it is necessary for community pharmacists to demonstrate the benefits of their interventions in terms of better outcomes whether they be clinical, economic and humanistic, and that the improvement is achieved at a cost acceptable to the healthcare system. Without the evidence of acceptable cost effectiveness and perceived benefits, any attempt to promote the implementation of pharmaceutical care by community pharmacists, especially in countries where the concept is relatively new, would only be perceived as lobbying for the interest of a particular professional group, and could not be justifiable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Higby GJ. Evolution of pharmacy in Remington’s pharmaceutical sciences. In: Gennaro AR, editor. Remington: the science and practice of pharmacy. 18th ed. Easton (PA): Mack Publishing Company, 1990: 8–19.

    Google Scholar 

  2. Schneider JK, Nickman NA. Assessment of pharmaceutical care needs in an ambulatory setting. Hosp Pharm 1994; 29: 238–42.

    PubMed  CAS  Google Scholar 

  3. Higby GJ. From compounding to caring: an abridged history of American pharmacy. In: Knowlton CH, Penna RP, editors. Pharmaceutical care. New York: Chapman & Hall, 1996: 18–54.

    Google Scholar 

  4. Angaran DM, Bonal J, Eide G, et al. Clinical pharmacy: looking 20 years back. looking 20 years forward. Pharmacotherapy 2000; 20: 235S–42S.

    Article  PubMed  CAS  Google Scholar 

  5. Christensen DB, Campbell WH, Madsen S, et al. Documenting outpatient problem intervention activities of pharmacists in an HMO. Med Care 1981; 19: 104–17.

    Article  PubMed  CAS  Google Scholar 

  6. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control: a four-year analysis of an ambulatory care model. Arch Intern Med 1984; 144: 1159–62.

    Article  PubMed  CAS  Google Scholar 

  7. Hammarlund ER, Ostrom JR, Kethley AJ. The effects of drug counseling and other educational strategies on drug utilization of the elderly. Med Care 1985; 23: 165–70.

    Article  PubMed  CAS  Google Scholar 

  8. Ives TJ, Frey JJ, Furr SJ, et al. Effect of an educational intervention on oral cephalosporin use in primary care. Arch Intern Med 1987; 147: 44–7.

    Article  PubMed  CAS  Google Scholar 

  9. Forstrom MJ, Ried LD, Stergachis AS, et al. Effect of a clinical pharmacist program on the cost of hypertension treatment in an HMO family practice clinic. Drug Intell Clin Pharm 1990; 24: 304–9.

    CAS  Google Scholar 

  10. Ibrahim OM, Catania PN, Mergener MA, et al. Outcome of cholesterol screening in a community pharmacy. Drug Intell Clin Pharm 1990; 24: 817–21.

    CAS  Google Scholar 

  11. Sidel VW, Beizer JL, Lisi-Fazio D, et al. Controlled study of the impact of educational home visits by pharmacists to high-risk older patients. J Community Health 1990; 15: 163–74.

    Article  PubMed  CAS  Google Scholar 

  12. Knoell KR, Leeds AL. Influenza vaccination program for elderly outpatients. Am J Hosp Pharm 1991; 48: 256–9.

    PubMed  CAS  Google Scholar 

  13. Rupp MT. Value of community pharmacists’ interventions to correct prescribing errors. Ann Pharmacother 1992; 26: 1580–4.

    PubMed  CAS  Google Scholar 

  14. Hartlaub PP, Barrett PH, Marine WM, et al. Evaluation of an intervention to change benzodiazepine-prescribing behavior in a prepaid group practice setting. Am J Prev Med 1993; 9: 346–52.

    PubMed  CAS  Google Scholar 

  15. Hunter KA, Bryant BG. Pharmacist provided education and counseling for managing pediatric asthma. Patient Educ Couns 1994; 24: 127–34.

    Article  PubMed  CAS  Google Scholar 

  16. De Santis G, Harvey KJ, Howard D, et al. Improving the quality of antibiotic prescription patterns in general practice: the role of educational intervention. Med J Aust 1994; 160: 502–5.

    PubMed  Google Scholar 

  17. Yeo GT, de Burgh SP, Letton T, et al. Educational visiting and hypnosedative prescribing in general practice. Fam Pract 1994; 11: 57–61.

    Article  PubMed  CAS  Google Scholar 

  18. Diwan VK, Wahlstrom R, Tomson G, et al. Effects of ‘group detailing’ on the prescribing of lipid-lowering drugs: a randomized controlled trial in Swedish primary care. J Clin Epidemiol 1995; 48: 705–11.

    Article  PubMed  CAS  Google Scholar 

  19. Ferguson RI, Salmond CE, Maling TJ. The Nelson Prescribing Project: a programmed intervention in general practice in New Zealand. Pharmacoeconomics 1995; 7: 555–61.

    Article  PubMed  CAS  Google Scholar 

  20. Johnson KA, Nye M, Hill-Besinque K, et al. Measuring of impact of patient counseling in the outpatient pharmacy setting: development and implementation of the counseling models for the Kaiser Permanente/USC Patient Consultation Study. Clin Ther 1995; 17: 988–1002.

    Article  PubMed  CAS  Google Scholar 

  21. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996; 100: 428–37.

    Article  PubMed  CAS  Google Scholar 

  22. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996; 30: 238–43.

    PubMed  CAS  Google Scholar 

  23. Anon. Pharmacist intervention in depression is focus of $3 million research grant [news]. Am J Health Syst Pharm 1997; 54: 2668.

  24. Munroe WP, Kunz K, Dalmady-Israel C, et al. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther 1997; 19: 113–23.

    Article  PubMed  CAS  Google Scholar 

  25. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997; 31: 713–9.

    PubMed  CAS  Google Scholar 

  26. Crealey GE, McElnay JC, Maguire TA, et al. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 1998; 14: 323–33.

    Article  PubMed  CAS  Google Scholar 

  27. Read RW, Krska J. Targeted medication review: patients in the community with chronic pain. Int J Pharm Pract 1998; 6: 216–22.

    Article  Google Scholar 

  28. Mayer JA, Slymen DJ, Eckhardt L, et al. Skin cancer prevention counseling by pharmacists: specific outcomes of an intervention trial. Cancer Detect Prev 1998; 22: 367–75.

    Article  PubMed  CAS  Google Scholar 

  29. Berringer R, Shibley MC, Cary CC, et al. Outcomes of a community pharmacybased diabetes monitoring program. J Am Pharm Assoc 1999; 39: 791–7.

    CAS  Google Scholar 

  30. Freemantle N, Eccles M, Wood J, et al. A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials 1999; 20: 479–92.

    Article  PubMed  CAS  Google Scholar 

  31. Hawksworth GM, Corlett AJ, Wright DJ, et al. Clinical pharmacy interventions by community pharmacists during the dispensing process. Br J Clin Pharmacol 1999; 47: 695–700.

    Article  PubMed  CAS  Google Scholar 

  32. Lundborg CS, Wahlstrom R, Diwan VK, et al. Combining feedback from simulated cases and prescribing: design and implementation of an educational intervention in primary care in Sweden. Int J Technol Assess Health Care 1999; 15: 458–72.

    PubMed  CAS  Google Scholar 

  33. Rodgers S, Avery AJ, Meechan D, et al. Controlled trial of pharmacist intervention in general practice: the effect on prescribing costs. Br J Gen Pract 1999; 49: 717–20.

    PubMed  CAS  Google Scholar 

  34. Tsuyuki RT, Johnson JA, Teo KK, et al. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999; 33: 910–9.

    Article  PubMed  CAS  Google Scholar 

  35. Blakey SA, Hixson-Wallace JA. Clinical and economic effects of pharmacy services in geriatric ambulatory clinic. Pharmacotherapy 2000; 20: 1198–203.

    Article  PubMed  CAS  Google Scholar 

  36. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000; 20: 1384–9.

    Article  PubMed  CAS  Google Scholar 

  37. Narhi U, Airaksinen M, Tanskanen P, et al. Therapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. J Clin Pharm Ther 2000; 25: 177–83.

    Article  PubMed  CAS  Google Scholar 

  38. Nola KM, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000; 40: 166–73.

    CAS  Google Scholar 

  39. Triller DM, Hamilton RA, Briceland LL, et al. Home care pharmacy: extending clinical pharmacy services beyond infusion therapy. Am J Health Syst Pharm 2000; 57: 1326–31.

    PubMed  CAS  Google Scholar 

  40. Williams DM, Newsom JF, Brock TP. An evaluation of smoking cessation-related activities by pharmacists. J Am Pharm Assoc 2000; 40: 366–70.

    CAS  Google Scholar 

  41. Allard J, Hebert R, Rioux M, et al. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for communitydwelling elderly people. CMAJ 2001; 164: 1291–6.

    PubMed  CAS  Google Scholar 

  42. Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30: 205–11.

    Article  PubMed  CAS  Google Scholar 

  43. MacFadyen L, Eadie D, McGowan T. Community pharmacists’ experience of over-the-counter medicine misuse in Scotland. J R Soc Health 2001; 121: 185–92.

    Article  CAS  Google Scholar 

  44. Simpson SH, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 2001; 21: 627–35.

    Article  PubMed  CAS  Google Scholar 

  45. Van Amburgh JA, Waite NM, Hobson EH, et al. Improved influenza vaccination rates in a rural population as a result of a pharmacist-managed immunization campaign. Pharmacotherapy 2001; 21: 1115–22.

    Article  PubMed  Google Scholar 

  46. Zermansky AG, Petty DR, Raynor DK, et al. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001; 323: 1340–3.

    Article  PubMed  CAS  Google Scholar 

  47. Benrimoj SI, Langford JH, et al. Economic impact of increased clinical intervention rates in community pharmacy: a randomised trial of the effect of education and a professional allowance. Pharmacoeconomics 2000; 18: 459–68.

    Article  PubMed  CAS  Google Scholar 

  48. Nau DP, Ponte CD. Effects of a commmunity pharmacist-based diabetes patientmanagement program on intermiate clinical outcome measures. J Managed Care Pharm 2002; 8: 48–53.

    Google Scholar 

  49. Strand LM, Guerrero RM, Nickman NA, et al. Integrated patient-specific model of pharmacy practice. Am J Hosp Pharm 1990; 47: 550–4.

    PubMed  CAS  Google Scholar 

  50. Smith MC. Pharmacy education? J Am Pharm Assoc 1970; NS10: 548–51.

    Google Scholar 

  51. Summers KH. The ‘rebirth’ of cognitive services. In: Smith MC, Wertheimer AI, editors. Social and behavioral aspects of pharmaceutical care. Binghamton (NY): Haworth Press, 1996: 675–714.

    Google Scholar 

  52. Van Mil JWF. Pharmaceutical care [PhD dissertation]. Rijksuniveriteit Groningen, 1998.

  53. Mikael RL, Brown TR, Lazarus HL, et al. Quality of pharmaceutical care in hospitals. Am J Hosp Pharm 1975; 32: 567–74.

    Google Scholar 

  54. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43.

    PubMed  CAS  Google Scholar 

  55. Hepler CD. The future of pharmacy: pharmaceutical care. Am Pharm 1990; 10: 23–9.

    Google Scholar 

  56. American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am J Hosp Pharm 1993; 50: 1720–3.

    Google Scholar 

  57. Pharmaceutical Society of Australia. Position paper on pharmaceutical care. Deakin (VIC): Pharmaceutical Society of Australia, 1997 Oct.

  58. International Pharmaceutical Federation (FIP). FIP statement of professional standards 1998 [online]. Available from URL: http://www.exist.nl/pdf/pharmcare.pdf [Accessed 2002 Feb 14].

  59. Getting Research into Pharmacy Practice Working Group. Medicines, pharmacy and the NHS: getting it right for patients and prescribers — setting the clinical effectiveness agenda for pharmacy [summary paper]. London: Royal Pharmaceutical Society of Great Britain, 1999 Jul.

  60. American Pharmaceutical Association. Pharmaceutical care: principles and practices. Available from URL: http://www.aphanet.org/pharmcare/prinprac.html [Accessed 2002 Feb 14].

  61. Plumridge RJ. Drug interactions: incidence in Victoria [letter]. Med J Aust 1982 May 1; 1:371.

    PubMed  CAS  Google Scholar 

  62. Beller SA, Evans ER. Drug therapy in the elderly: effects on mental status. Am Fam Physician 1987; 36: 149–52.

    PubMed  CAS  Google Scholar 

  63. Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992; 47: M137–44.

    Article  PubMed  CAS  Google Scholar 

  64. Leibovici MM. Patient management and use of medication in long-term care. Health Care Manag 1997; 3: 77–86.

    PubMed  CAS  Google Scholar 

  65. Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666–71.

    Article  PubMed  CAS  Google Scholar 

  66. Malhotra S, Karan RS, Pandhi P, et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001; 77: 703–7.

    Article  PubMed  CAS  Google Scholar 

  67. Sarlov C, Andersen-Karlsson E, von Bahr C. Adverse effects of drugs in patients with heart disease lead to hospital care. Lakartidningen 2001; 98: 5349–53.

    PubMed  CAS  Google Scholar 

  68. Hanlon JT, Fillenbaum GG, Kuchibhatla M, et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care 2002; 40: 166–76.

    Article  PubMed  Google Scholar 

  69. McMillan DA, Harrison PM, Rogers LJ, et al. Polypharmacy in an Australian teaching hospital: preliminary analysis of prevalence, types of drugs and associations. Med J Aust 1986; 145: 339–42.

    PubMed  CAS  Google Scholar 

  70. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992; 117: 684–9.

    PubMed  CAS  Google Scholar 

  71. Beers MH, Fingold SF, Ouslander JG, et al. Characteristics and quality of prescribing by doctors practicing in nursing homes. J Am Geriatr Soc 1993; 41: 802–7.

    PubMed  CAS  Google Scholar 

  72. Wilcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272: 292–6.

    Article  Google Scholar 

  73. Gupta S, Rappaport HM, Bennett LT. Polypharmacy among nursing home geriatric Medicaid recipients. Ann Pharmacother 1996; 30: 946–50.

    PubMed  CAS  Google Scholar 

  74. Aparasu RR, Fliginger SE. Inappropriate medication prescribing for the elderly by office-based physicians. Ann Pharmacother 1997; 31: 823–9.

    PubMed  CAS  Google Scholar 

  75. Dyer CC, Oles KS, Davis SW. The role of the pharmacist in a geriatric nursing home: a literature review. Drug Intell Clin Pharm 1984; 18: 428–33.

    PubMed  CAS  Google Scholar 

  76. Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug associated hospital admission in older medical patients. J Am Geriatr Soc 1988; 36: 1092–8.

    PubMed  CAS  Google Scholar 

  77. Colt HG, Shapiro AP. Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc 1989; 37: 323–6.

    PubMed  CAS  Google Scholar 

  78. Ruiz JG, Array S, Lowenthal DT. Avoiding overmedication of elderly patients. Am J Ther 1996; 3: 784–8.

    Article  PubMed  Google Scholar 

  79. Monane M, Avorn J. Medications and falls: causation, correlation, and prevention. Clin Geriatr Med 1996; 12: 847–58.

    PubMed  CAS  Google Scholar 

  80. Gerdtham U-G, Johannesson M, Jönsson B. Drug costs and new drug introductions: the Swedish experience. Pharmacoeconomics 1993; 4: 215–25.

    Article  PubMed  CAS  Google Scholar 

  81. Card G. TV, drugs, and health care: evaluating and combating the influence of direct-to-consumer advertising on the prescription drug market. Harvard Health Pol Rev 2001; 2: 77–86.

    Google Scholar 

  82. Sloan C. A history of the pharmaceutical benefits scheme: 1947–1992. Canberra: Australian Government Publishing Services, 1995.

    Google Scholar 

  83. Anon. Medicare fact sheet 10: the pharmaceutical benefits scheme (PBS). New Doctor 2001 Winter; 75: 18–20.

  84. Canadian Institute for Health Information (CHI). Spending on drugs outpaces other health care spending: drug expenditures in Canada 1985–2000 [media release] 2001 Mar 14.

  85. Anon. Managed pharmacy benefits: rising drug costs. MPB Script Talk 2000 Winter; 2: 3.

  86. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980; 9: 73–80.

    Article  PubMed  CAS  Google Scholar 

  87. Inman WH. Under-reporting of adverse drug reactions [letter]. BMJ 1985; 290: 1355.

    Article  PubMed  CAS  Google Scholar 

  88. Nolan L, O’Malley K. Prescribing for the elderly: part 1. sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9.

    PubMed  CAS  Google Scholar 

  89. Hoigné R, Lawson DH, Weber E. Risk factors for adverse drug reactions: epidemiological approaches. Eur J Clin Pharmacol 1990; 39: 321–5.

    Article  PubMed  Google Scholar 

  90. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA 1975; 234: 1236–41.

    Article  PubMed  CAS  Google Scholar 

  91. World Health Organization. Requirements for adverse drug reaction reporting. Geneva: World Health Organization, 1975.

    Google Scholar 

  92. Hershey LA. Avoiding adverse drug reactions in the elderly. Mt Sinai J Med 1988; 55: 244–50.

    PubMed  CAS  Google Scholar 

  93. DeSwarte RD. Drug allergies: problems and strategies. J Allergy Clin Immunol 1984; 74: 209–24.

    Article  Google Scholar 

  94. American Society of Hospital Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Hosp Pharm 1989; 36: 336–7.

    Google Scholar 

  95. Ioannides-Demos LL, Eckert GM, McLean AJ. Pharmacoeconomic consequences of measurement and modification of hospital drug use. Pharmacoeconomics 1992; 2: 15–33.

    Article  PubMed  CAS  Google Scholar 

  96. Prince BS, Goetz CM, Rihn TL, et al. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49: 1696–700.

    PubMed  CAS  Google Scholar 

  97. Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy 1996; 16: 701–7.

    PubMed  CAS  Google Scholar 

  98. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–6.

    Article  PubMed  CAS  Google Scholar 

  99. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324: 370–6.

    Article  PubMed  CAS  Google Scholar 

  100. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug reactions in hospital patients. JAMA 1991; 266: 2847–51.

    Article  PubMed  CAS  Google Scholar 

  101. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 337–84.

    Article  Google Scholar 

  102. Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309–14.

    Article  PubMed  CAS  Google Scholar 

  103. Stanaszek WF, Franklin CE. Survey of potential drug interaction incidence in an outpatient clinic population. Hosp Pharm 1978; 13: 255–63.

    PubMed  CAS  Google Scholar 

  104. Schneider JK, Mion LC, Frengley JD. Adverse drug reaction in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–6.

    PubMed  CAS  Google Scholar 

  105. Schneider PJ, Gift MG, Lee YP, et al. Cost of medication-related problem at a university hospital. Am J Health Syst Pharm 1995; 52: 2415–8.

    PubMed  CAS  Google Scholar 

  106. Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164: 659–62.

    PubMed  CAS  Google Scholar 

  107. Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health Syst Pharm 1996; 53: 1422–6.

    PubMed  CAS  Google Scholar 

  108. Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, et al. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997; 53: 19–22.

    Article  PubMed  CAS  Google Scholar 

  109. Schliener RG, Oh PI, Knowles SR, et al. Quantifying the costs of serious drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl. 7: S27–32.

    Article  Google Scholar 

  110. Lagnaoui Rl, Moore N, Fach J, et al. Adverse drug reactions in a department of systematic disease-orientated internal medicine: prevalence, incidence, direct cost and affordability. Eur J Clin Pharmacol 2000; 56: 181–6.

    Article  PubMed  CAS  Google Scholar 

  111. Suh DC, Woodal BS, Shin SK, et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34: 1373–9.

    PubMed  CAS  Google Scholar 

  112. Schumock GT. Methods to assess the economic outcomes of clinical pharmacy services. Pharmacotherapy 2000; 20: 243S–52S.

    Article  PubMed  CAS  Google Scholar 

  113. Hurley SF, McNeil JJ, Jolley DJ, et al. Linking prescription and patient-identifying data: a pilot study. Med J Aust 1992; 156: 383–6.

    PubMed  CAS  Google Scholar 

  114. Scheitel SM, Fleming KC, Chutka DS, et al. Geriatric health maintenance. Mayo Clin Proc 1996; 71: 289–302.

    Article  PubMed  CAS  Google Scholar 

  115. Stern A. Disease management: modeling the future of health care. Healthplan 2001; 42: 14–8.

    PubMed  CAS  Google Scholar 

  116. Maine LL, Penna RP. Pharmaceutical care: an overview. In: Knowlton CH, Penna RP, editors. Pharmaceutical care. New York: Chapman & Hall, 1996: 133–54.

    Google Scholar 

  117. Bodenheimer T. Disease management: promises and pitfalls. N Engl J Med 1999; 340: 1202–5.

    Article  PubMed  CAS  Google Scholar 

  118. Hunter DJ, Fairfield G. Disease management. BMJ 1997; 315: 50–3.

    Article  PubMed  CAS  Google Scholar 

  119. Boston Consulting Group. The promise of disease management. Boston (MA): The Boston Consulting Group Inc, 1995.

    Google Scholar 

  120. Ellrodt G, Cook DJ, Lee J, et al. Evidence-based disease management. JAMA 1997; 278: 1687–92.

    Article  PubMed  CAS  Google Scholar 

  121. Gilmour P, Hunt RA. Total quality management: integrating quality into design, operations and strategy. Cheshire: Longman, 1995.

    Google Scholar 

  122. Cordina M, McElnay JC, Hughes CM. Assessment of a community-based program for patients with asthma. Pharmacotherapy 2001; 21: 1196–203.

    Article  PubMed  CAS  Google Scholar 

  123. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacistmanaged hypertension clinic. Pharmacotherapy 2001; 21: 1337–44.

    Article  PubMed  CAS  Google Scholar 

  124. Needham DS, Wong IC, Campion PD, et al. Evaluation of the effectiveness of UK community pharmacists’ interventions in community palliative care. Palliat Med 2002; 16(3): 219–25.

    Article  PubMed  CAS  Google Scholar 

  125. Bernsten C, Bjorkman I, Caramona M, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study of seven European countries. Drugs Aging 2001; 18(1): 63–77.

    Article  PubMed  CAS  Google Scholar 

  126. Pickard AS, Johnson JA, Faris KB. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother 1999; 33(11): 1167–72.

    Article  PubMed  CAS  Google Scholar 

  127. Novartis. Pharmacy benefit report. East Hanover (NJ): Novartis, 1997.

    Google Scholar 

  128. Anon. Reimbursement for pharmacy services: a rock and a hard place. Trends 2001: The Pharmacy Report. Toronto (ONT): Rogers Media-Healthcare & Financial Publishing.

  129. Commonwealth of Australia. Health and medical research strategic review: case study. Canberra (ACT): Department of Health and Aged Care, Australian Government Publishing Services, 1988 Dec 4.

  130. van Mil JWF, De Boer WO, Tromp ThFJ. European barriers to the implementation of pharmaceutical care. Int J Pharm Pract 2001; 9: 163–8.

    Article  Google Scholar 

  131. Joint International Forum. World-wide developments in pharmaceutical care. Pharm J 1998; 260: 563–8.

    Google Scholar 

  132. Antipodean review of developments: Third International Symposium on Pharmaceutical Care [editorial]. Pharm J 2000; 264; 7100: 884–7.

    Google Scholar 

  133. Carroll NV. Consumer demand for patient orientated services in community pharmacies: a review and comment. J Soc Admin Pharm 1985; 3: 64–9.

    Google Scholar 

  134. Carroll NV, Perri III M, Eve EE, et al. Estimating demand for health information: pharmacy counselling services. J Health Care Market 1987; 7: 33–40.

    CAS  Google Scholar 

  135. Robinson B. Cardiac risk screening gets Florida pharmacy test [news]. Drug Top 1988; 132: 12.

    Google Scholar 

  136. Meade V. Conducting at-home medication reviews. Am Pharm 1992; NS32: 37–9.

    Google Scholar 

  137. Suh D. Consumers’ willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc 2000; 40: 818–27.

    CAS  Google Scholar 

  138. Larson RA. Patients’ willingness to pay for pharmaceutical care. J Am Pharm Assoc 2000; 40(5): 618–24.

    CAS  Google Scholar 

  139. Li SC, Chan SY, How PPC. A preliminary study of provision of pharmaceutical care in community pharmacy in Singapore: cost analysis and patient’s willingness to pay. Value Health 2000; 3:116.

    Article  Google Scholar 

  140. Broeseker A, Janke KK. The evolution and revolution of pharmaceutical care. In: McCarthy RL, editor. Introduction to health care delivery: a primer for pharmacists. Gaithersburg (MD): Aspen Publishers Inc, 1998: 393–416.

    Google Scholar 

  141. Penna RP. Pharmaceutical care: pharmacy’s mission for the 1990s. Am J Hosp Pharm 1990; 47: 543–9.

    PubMed  CAS  Google Scholar 

  142. Barner JC, Bennett RW. Pharmaceutical care certificate program: assessment of pharmacists’ implementation into practice. J Am Pharm Assoc (Wash) 1999 May-Jun; 39(3): 362–7.

    CAS  Google Scholar 

  143. Miller MJ, Ortmeier BG. Factors influencing the delivery of pharmacy services. Am Pharm 1995 Jan; NS35(1): 39–45.

    PubMed  CAS  Google Scholar 

  144. Cordina M, McElnay JC, Hughes CM. The importance that pharmacists in Malta place on the introduction of pharmaceutical care. Pharm World Sci 1999; 21: 69–73.

    Article  PubMed  CAS  Google Scholar 

  145. Erickson SR, Landino HM, Zarowitz BJ, et al. Pharmacists’ understanding of patient education on metered-dose inhaler technique. Ann Pharmacother 2000; 34(11): 1249–56.

    Article  PubMed  CAS  Google Scholar 

  146. Norwood GJ, Sleath BL, Caiola SM, et al. Costs of implementing pharmaceutical care in community pharmacies. J Am Pharm Assoc 1998; 38: 755–61.

    CAS  Google Scholar 

  147. Albro W. How to communicate with physicians. Am Pharm 1993; NS33: 59–61.

    PubMed  CAS  Google Scholar 

  148. Butenya GB, Lauwo JAK. Communication about dispensed drugs between prescriber, the dispenser and the patient: a study from Port Moresby General Hospital. Aust J Hosp Pharm 1993; 23: 182–5.

    Google Scholar 

  149. Smith WE, Ray MD, Shannon DM. Physicians’ expectations of pharmacists. Am J Health Syst Pharm 2002; 59: 50–7.

    PubMed  Google Scholar 

  150. Hynniman CE, Lamy PP. Physicians view the pharmacist. J Am Pharm Assoc 1971; NS11: 158–63, 180.

    Google Scholar 

  151. Williamson RE, Kabat HF. Pharmacist/physician drug communications. J Am Pharm Assoc 1971; NS11: 164–7.

    Google Scholar 

  152. How PPC. Evaluation of pharmaceutical care services provided by community pharmacists in Singapore [Honours dissertation]. National University of Singapore, 1999.

  153. Amsler MR, Murray MD, Tierney WM, et al. Pharmaceutical care in chain pharmacies: beliefs and attitudes of pharmacists and patients. J Am Pharm Assoc 2001; 41: 850–5.

    CAS  Google Scholar 

  154. Quintrell N. Communication skills: a manual for pharmacists. Canberra: Pharmaceutical Society of Australia, 1982.

    Google Scholar 

  155. Poulton BC, West MA. Effective multidisciplinary teamwork in primary health care. J Adv Nurs 1993; 18: 918–25.

    Article  PubMed  CAS  Google Scholar 

  156. Clemmer TP, Spuhler VJ, Berwick DM, et al. Cooperation: the foundation of improvement. Ann Intern Med 1998; 128: 1004–9.

    PubMed  CAS  Google Scholar 

  157. McDonough RP, Doucette WR. Dynamics of pharmaceutical care: developing collaborative working relationships between pharmacists and physicians. J Am Pharm Assoc 2001; 41: 682–92.

    Google Scholar 

  158. Meade V. Helping pharmacists provide disease-based pharmaceutical care. Am Pharm 1995; 35: 45–8.

    Google Scholar 

  159. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice. New York: McGraw-Hill Co Inc, 1998.

    Google Scholar 

Download references

Acknowledgements

The author declares that no funding from any source was received for the preparation of this manuscript and that there is no potential conflict of interest directly relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, 119260, Singapore

    Shu Chuen Li PhD, MBA (Assistant Professor)

Authors
  1. Shu Chuen Li PhD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shu Chuen Li PhD, MBA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chuen Li, S. An Overview of Community Pharmacist Interventions. Dis-Manage-Health-Outcomes 11, 95–110 (2003). https://doi.org/10.2165/00115677-200311020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200311020-00004

Keywords

Search

Navigation